Respiri Limited released its earnings results on Feb 29, 2024. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.

Q: Is Respiri Limited overvalued?

According to Wall Street analysts Respiri Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: How many shares outstanding does Respiri Limited have?

Respiri Limited has 1,059,868,900 shares outstanding.

Q: What happened to Respiri Limited’s price movement after its last earnings report?

Respiri Limited reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

4 Followers

RSHUF Stock Chart & Stats

Advanced Chart >

Day’s Range$0 - $0

52-Week Range<$0.01 - $0.06

Previous Close$0.01

Volume105.00K

Average Volume (3M)N/A

Market Cap

$20.76M

Enterprise Value$20.01M

Total Cash (Recent Filing)AU$1.22M

Total Debt (Recent Filing)AU$70.66K

Price to Earnings (P/E)-2.0

Beta0.23

Next Earnings

Aug 28, 2024

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,059,868,924

10 Day Avg. Volume0

30 Day Avg. VolumeN/A

Standard Deviation0.54

R-Squared0.00047

Alpha0.05

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Respiri Limited News

PremiumCompany Announcements

Respiri Limited Secures Major Contract in Hawaii

5h ago

PremiumCompany Announcements

Respiri Limited Shareholders Back Growth Strategy

11d ago

See More RSHUF News >

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

23.97% Insiders

0.00% Mutual Funds

0.00% Other Institutional Investors

76.03% Public Companies and

Individual Investors

Detailed Ownership Overview >

RSHUF FAQ

What was Respiri Limited’s price range in the past 12 months?

Respiri Limited lowest stock price was <$0.01 and its highest was $0.06 in the past 12 months.

What is Respiri Limited’s market cap?

Currently, no data Available

When is Respiri Limited’s upcoming earnings report date?

Respiri Limited’s upcoming earnings report date is Aug 28, 2024 which is in 121 days.

How were Respiri Limited’s earnings last quarter?

Respiri Limited released its earnings results on Feb 29, 2024. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.

Is Respiri Limited overvalued?

According to Wall Street analysts Respiri Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Respiri Limited pay dividends?

Respiri Limited does not currently pay dividends.

What is Respiri Limited’s EPS estimate?

Respiri Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Respiri Limited have?

Respiri Limited has 1,059,868,900 shares outstanding.

What happened to Respiri Limited’s price movement after its last earnings report?

Respiri Limited reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Respiri Limited?

Currently, no hedge funds are holding shares in RSHUF

---

Respiri Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-218.09%

Trailing 12-Months

Asset Growth

95.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Respiri Limited

Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. Its proprietary apps, software, and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes, and reduce healthcare expenditures. It operates through the Australia and Israel segments. The Australia segment includes research, development, and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment refers to the research, development and, commercialization of medical devices, and the production of mobile health applications in Israel. The company was founded by Noam Gavriely in 1987 and is headquartered in Melbourne, Australia.

---